CFO of Acurx (NASDAQ: ACXP) receives 25,900 stock options award

Rhea-AI Filing Summary

Acurx Pharmaceuticals, Inc. reported that its Chief Financial Officer, Robert G. Shawah, received a grant of stock options covering 25,900 shares of common stock on April 20, 2026.

The options have an exercise price of $2.36 per share, expire on April 20, 2036, and vest in 36 equal monthly installments starting on the grant date. After this grant, he holds stock options for 25,900 shares directly as reported in this filing. This is a compensation-related award rather than an open-market share purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Shawah Robert G.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	25,900	$0.00	--

Holdings After Transaction: Stock Option — 25,900 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 25,900 options Exercise price: $2.36 per share Expiration date: April 20, 2036 +2 more

5 metrics

Stock options granted 25,900 options Grant to CFO on April 20, 2026

Exercise price $2.36 per share Strike price for granted options

Expiration date April 20, 2036 Option term for CFO grant

Vesting schedule 36 monthly installments Vesting begins on April 20, 2026

Total options after grant 25,900 options Directly held per Form 4 after transaction

Key Terms

Stock Option, Grant Date, vest, exercise price, +1 more

5 terms

Stock Option financial

"the Reporting Person was granted stock options to purchase 25,900 shares"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Grant Date financial

"On April 20, 2026 (the "Grant Date"), the Reporting Person was granted"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

vest financial

"These options vest in 36 equal monthly installments commencing on the Grant Date"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"conversion_or_exercise_price": "2.3600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shawah Robert G.

(Last) (First) (Middle)

C/O ACURX PHARMACEUTICALS, INC.,

259 LIBERTY AVENUE

(Street)

STATEN ISLAND NEW YORK 10305

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acurx Pharmaceuticals, Inc. [ ACXP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$2.36	04/20/2026		A		25,900		(1)	04/20/2036	Common Stock	25,900	$0	25,900	D

Explanation of Responses:

1. On April 20, 2026 (the "Grant Date"), the Reporting Person was granted stock options to purchase 25,900 shares of the Issuer's common stock. These options vest in 36 equal monthly installments commencing on the Grant Date.

	/s/ Kostantinos Skordalos, Power of Attorney For: Robert G. Shawah	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Acurx Pharmaceuticals (ACXP) report for its CFO?

Acurx Pharmaceuticals reported that CFO Robert G. Shawah received a grant of stock options for 25,900 shares of common stock. This award is compensation-related and not an open-market trade, reflecting additional potential equity exposure if the options are exercised in the future.

What is the exercise price of the Acurx (ACXP) stock options granted to the CFO?

The granted stock options have an exercise price of $2.36 per share. This means the CFO can buy Acurx common stock at $2.36 if he exercises the options, regardless of the market price, once the options have vested and before they expire.

When do the newly granted Acurx (ACXP) CFO stock options vest and expire?

The options granted to the CFO vest in 36 equal monthly installments beginning on April 20, 2026. They expire on April 20, 2036, giving a 10-year window from the grant date during which vested options can be exercised, subject to plan terms.

How many Acurx (ACXP) stock options does the CFO hold after this Form 4 filing?

After the reported grant, the Form 4 shows the CFO holding stock options for 25,900 underlying shares directly. These options were all issued in this grant, and their future value depends on Acurx’s share price relative to the $2.36 exercise price.

Was the Acurx (ACXP) CFO’s transaction a market purchase or sale of shares?

No. The Form 4 shows a grant of stock options coded as an award, not a market buy or sell. The CFO did not purchase or sell existing shares; he received options that may allow future purchases at $2.36 per share once vested.